Cheryl A. London

Biochemical Mechanisms of IL-2–Regulated Fas-Mediated T Cell Apoptosis

Yosef Refaeli, Luk Van Parijs, Cheryl A. London et al. · Immunity · 1998 · 633 citations · Full text

Inflammation, Medicine, Apoptosis +9

Response evaluation criteria for solid tumours in dogs (v1.0): a Veterinary Cooperative Oncology Group (<scp>VCOG</scp>) consensus document

Sandra Nguyen, Douglas H. Thamm, David M. Vail et al. · Veterinary and Comparative Oncology · 2013 · 417 citations

Veterinary Medical Oncology, Consensus Document, Medicine +14

Multi-center, Placebo-controlled, Double-blind, Randomized Study of Oral Toceranib Phosphate (SU11654), a Receptor Tyrosine Kinase Inhibitor, for the Treatment of Dogs with Recurrent (Either Local or Distant) Mast Cell Tumor Following Surgical Excision

Cheryl A. London, Phyllis B. Malpas, Stacey L. Wood-Follis et al. · Clinical Cancer Research · 2009 · 416 citations · Full text

Functional Responses and Costimulator Dependence of Memory CD4+ T Cells

Cheryl A. London, Michael P. Lodge, Abul K. Abbas · The Journal of Immunology · 2000 · 317 citations

Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies.

Cheryl A. London, Alison L. Hannah, Regina Zadovoskaya et al. · PubMed · 2003 · 288 citations

Chemoprevention Strategy, Kinase Inhibitors, Pathology +16